<?xml version="1.0" encoding="UTF-8"?>
<p>Finally, developers of vaccines targeted at replacing BCG in infants will need to take into consideration the effects of BCG unrelated to protection against TB. BCG vaccination has been demonstrated to provide protection against leprosy, and this constitutes one of the bases for BCG recommendation 
 <sup>
  <xref rid="ref-13" ref-type="bibr">13</xref>
 </sup>. Studies of BCG-associated protection against Buruli ulcer disease, however, have demonstrated mixed results 
 <sup>
  <xref rid="ref-34" ref-type="bibr">34</xref>, 
  <xref rid="ref-35" ref-type="bibr">35</xref>
 </sup>. Improvement in all-cause mortality in LMICs has also been reported 
 <sup>
  <xref rid="ref-36" ref-type="bibr">36</xref>
 </sup>. Additionally, intravesicular BCG has been demonstrated to provide a significant degree of protection from recurrence of superficial bladder cancer as compared to chemotherapy 
 <sup>
  <xref rid="ref-37" ref-type="bibr">37</xref>
 </sup>. Ultimately, investments will need to be made to support clinical studies to fully evaluate all candidates intended to replace BCG, as well as any new TB vaccine.
</p>
